Myelofibrosis News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Ruxolitinib therapy appears safe prior to allogenic HSCT for myelofibrosis - Healio



Ruxolitinib therapy appears safe prior to allogenic HSCT for myelofibrosis 
Healio
SALT LAKE CITY ? Ruxolitinib treatment prior to allogeneic hematopoietic stem cell transplant appeared safe and aided in the prevention of cytokine release syndrome among patients with myelofibrosis, according to results of a phase 2 prospective study ...

 


Global Myelofibrosis API Manufacturers, Marketed and Phase III Drugs Landscape Research 2018 ... - Business Wire (press release)



Global Myelofibrosis API Manufacturers, Marketed and Phase III Drugs Landscape Research 2018 ... 
Business Wire (press release)
Myelofibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018' report provides comprehensive insights about marketed and Phase III products for Myelofibrosis . The report includes information of marketed products including ...

and more » 


Myelofibrosis Pipeline Research Report 2018 - Investor Opinion



Myelofibrosis Pipeline Research Report 2018 
Investor Opinion
Myelofibrosis- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all ...

and more » 


Myelofibrosis Market Pipeline, 2018 Therapeutics Development Drugs Profiles and Top Key Players - The Financial



Myelofibrosis Market Pipeline, 2018 Therapeutics Development Drugs Profiles and Top Key Players 
The Financial
Myelofibrosis Market Pipeline therapeutics 2018 presents an in-depth assessment of the pipeline (under development) therapeutics scenario and growth prospects across Myelofibrosis Market development. The report additionally provides detailed coverage ...

and more » 


Myelofibrosis Market 2018 Disease Type, Consulting Services, Symptoms, Analysis and Forecast - The Financial



Myelofibrosis Market 2018 Disease Type, Consulting Services, Symptoms, Analysis and Forecast 
The Financial
Myelofibrosis Market Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 ? marketed, Phase III products, Drugs Profiles and route of synthesis. The Myelofibrosis Market report is an in-depth market study providing accurate market ...

and more » 


Myelofibrosis (MF) Market Epidemiology Key Strengths, 7MM Coverage, Cases, Assessments and Forecast 2027 - The Financial



Myelofibrosis (MF) Market Epidemiology Key Strengths, 7MM Coverage, Cases, Assessments and Forecast 2027 
The Financial
Myelofibrosis (MF) Market ? Epidemiology Forecast, 2027 comprises of extensive primary research along with the detailed analysis by qualitative as well as quantitative aspects of Myelofibrosis (MF) Market epidemiology providing the historical and ...

and more » 


Imago BioSciences Receives FDA Approval of IND Application for the Treatment of Myeloid Malignancies - PR Newswire (press release)



Imago BioSciences Receives FDA Approval of IND Application for the Treatment of Myeloid Malignancies 
PR Newswire (press release)
"There is a pressing need for novel approaches to the treatment of myeloproliferative disorders including myelofibrosis," said Hugh Young Rienhoff, Jr. M.D., Imago's Chief Executive Officer. "We are pleased to have received FDA acceptance of our ...

and more » 


Myelofibrosis (MF) Market Report 2027: To understand the future market competition in the Myelofibrosis (MF) market. - The Financial



Myelofibrosis (MF) Market Report 2027: To understand the future market competition in the Myelofibrosis (MF) market. 
The Financial
Myelofibrosis (MF) ? Market Insights, Epidemiology and Market Forecast ? 2027?? report provides a detailed analysis of the Myelofibrosis (MF) epidemiology and market outlook for the 7MM.United States, EU5 (Germany, France, Italy, Spain, and the United ...

and more » 


Little Geron May Soon Be Nipping At The Heels Of Celgene And Incyte - Seeking Alpha



Little Geron May Soon Be Nipping At The Heels Of Celgene And Incyte 
Seeking Alpha
Geron's impending dominance in Myelofibrosis makes Celgene's $7B acquisition of Impact Biomedicines a tragic bungle. Geron may be the real nightmare Celgene's investors fear and may soon become reality as Imetelstat shows superior results compared to ...

 


Why Geron Corporation Stock Ripped Higher in January - Motley Fool



Wolcott Daily
 
Why Geron Corporation Stock Ripped Higher in January 
Motley Fool
Geron's stock has been a favorite target of short-sellers for most of the past year. One of the major reasons is a so-called "information request" from the U.S. Food and Drug Administration (FDA) pertaining to imetelstat's risk-to-reward ratio in ...
Financial Newsletter - Zacks Zacks
Geron Corporation - GERN - Stock Price Today - Zacks Zacks

all 67 news articles »